cyclacel limited is a pharmaceuticals company located in 46-48 e smithfield, london, united kingdom.
Company profile
Ticker
CYCC, CYCCP
Exchange
Website
CEO
Spiro Rombotis
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
XCYTE THERAPIES INC
SEC CIK
Corporate docs
IRS number
911766850
CYCC stock data
Latest filings (excl ownership)
S-1
IPO registration
25 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Cyclacel Pharmaceuticals Reports fourth quarter and full year 2023 financial results and provides business update
19 Mar 24
424B3
Prospectus supplement
14 Feb 24
EFFECT
Notice of effectiveness
14 Feb 24
CORRESP
Correspondence with SEC
12 Feb 24
S-1/A
IPO registration (amended)
8 Feb 24
CORRESP
Correspondence with SEC
7 Feb 24
8-K
Departure of Directors or Certain Officers
30 Jan 24
UPLOAD
Letter from SEC
26 Jan 24
Transcripts
CYCC
Earnings call transcript
2023 Q4
19 Mar 24
CYCC
Earnings call transcript
2023 Q3
13 Nov 23
CYCC
Earnings call transcript
2023 Q2
9 Aug 23
CYCC
Earnings call transcript
2023 Q1
11 May 23
CYCC
Earnings call transcript
2022 Q4
6 Mar 23
CYCC
Earnings call transcript
2022 Q3
10 Nov 22
CYCC
Earnings call transcript
2022 Q2
11 Aug 22
CYCC
Earnings call transcript
2022 Q1
12 May 22
CYCC
Earnings call transcript
2021 Q4
29 Mar 22
CYCC
Earnings call transcript
2021 Q3
11 Nov 21
Latest ownership filings
SC 13G/A
Schonfeld Strategic Advisors LLC
14 Feb 24
SC 13G/A
Dellora Investments LP
14 Feb 24
SC 13G/A
Altium Capital Management LP
13 Feb 24
SC 13G/A
ACORN BIOVENTURES, L.P.
7 Feb 24
4
BRIAN SCHWARTZ
31 Jan 24
SC 13G
Altium Capital Management LP
10 Jan 24
SC 13G
Lind Global Fund II LP
4 Jan 24
4
Paul McBarron
26 Dec 23
4
Spiro George Rombotis
26 Dec 23
4
Spiro George Rombotis
3 Jul 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.94 mm | 5.94 mm | 5.94 mm | 5.94 mm | 5.94 mm | 5.94 mm |
Cash burn (monthly) | 1.41 mm | 1.48 mm | 2.28 mm | 2.43 mm | 1.35 mm | 1.45 mm |
Cash used (since last report) | 8.36 mm | 8.80 mm | 13.56 mm | 14.46 mm | 8.00 mm | 8.60 mm |
Cash remaining | -2.42 mm | -2.85 mm | -7.62 mm | -8.52 mm | -2.05 mm | -2.66 mm |
Runway (months of cash) | -1.7 | -1.9 | -3.3 | -3.5 | -1.5 | -1.8 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 27 |
Opened positions | 2 |
Closed positions | 4 |
Increased positions | 5 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 222.47 mm |
Total shares | 5.29 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Acorn Bioventures | 2.82 mm | $0.00 |
Dellora Investments | 648.75 k | $0.00 |
Acadian Asset Management | 363.37 k | $124.00 k |
CVI Investments | 280.98 k | $2.19 mm |
Aspire Capital Fund | 270.00 k | $2.28 mm |
Point72 Asset Management | 230.00 k | $81.58 mm |
Renaissance Technologies | 185.50 k | $66.00 k |
Eastern Capital | 108.36 k | $436.00 k |
Vanguard | 86.95 k | $30.84 mm |
Geode Capital Management | 86.43 k | $29.99 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Jan 24 | Schwartz Brian | Common Stock | Grant | Acquire A | No | No | 0 | 12,500 | 0.00 | 15,205 |
29 Jan 24 | Schwartz Brian | Stock Option Common Stock | Grant | Acquire A | No | No | 2.28 | 12,500 | 28.50 k | 12,500 |
21 Dec 23 | Paul McBarron | Common Stock | Buy | Acquire P | No | No | 3.315 | 1,886 | 6.25 k | 33,378 |
21 Dec 23 | Paul McBarron | Warrants Common Stock | Buy | Acquire P | No | No | 3.19 | 1,886 | 6.02 k | 1,886 |
21 Dec 23 | Spiro George Rombotis | Common Stock | Buy | Acquire P | No | No | 3.315 | 6,070 | 20.12 k | 68,658 |
21 Dec 23 | Spiro George Rombotis | Warrants Common Stock | Buy | Acquire P | No | No | 3.19 | 6,070 | 19.36 k | 6,070 |
30 Jun 23 | Schwartz Brian | Common Stock | Grant | Acquire A | No | No | 0 | 21,219 | 0.00 | 40,602 |
30 Jun 23 | Schwartz Brian | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5891 | 42,438 | 25.00 k | 42,438 |
30 Jun 23 | Walker Karin L | Common Stock | Grant | Acquire A | No | No | 0 | 21,219 | 0.00 | 40,602 |
30 Jun 23 | Walker Karin L | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5891 | 42,438 | 25.00 k | 42,438 |
News
Earnings Outlook For Cyclacel Pharmaceuticals
18 Mar 24
Cyclacel Pharmaceuticals Announces Preclinical Proof-Of-Concept Data For Fadraciclib To Be Presented At The American Association For Cancer Research Annual Meeting 2024
7 Mar 24
Cyclacel Pharmaceuticals Announces Receipt Of $2.9M R&D Tax Credit
6 Mar 24
12 Health Care Stocks Moving In Monday's Intraday Session
15 Jan 24
12 Health Care Stocks Moving In Friday's Intraday Session
12 Jan 24
Press releases
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
7 Mar 24
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
6 Mar 24
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
30 Jan 24
Thinking about buying stock in Cyclacel Pharmaceuticals, Broadcom, Qualcomm, Esperion Therapeutics, or Arena Group?
8 Jan 24
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
8 Jan 24